<DOC>
	<DOC>NCT02821715</DOC>
	<brief_summary>This Phase 2 study is a 3-site, double-blind, randomised, placebo-controlled, 3-way cross-over trial, involving 3 treatments with Modafinil 300 mg or the combination drug THN102 (Modafinil/Flecainide 300 /3 mg, Modafinil/Flecainide 300 /27 mg).</brief_summary>
	<brief_title>Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients</brief_title>
	<detailed_description>The 3 double blind periods (2-week) follow a stabilisation period for modafinil at 300 mg/day (open, 2-week) and are followed by a one-week washout period with the same modafinil dose.</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Main inclusion Criteria: Patients with a diagnosis of narcolepsy type 1 (i.e. with cataplexy) or type 2 (without cataplexy) according to the International Classification of Sleep Disorders (ICSD3) criteria. Body mass index &gt;18 kg/m2 and &lt;35 kg/m2. Patients treated with modafinil at stable dosage for at least 2 months and still complaining of excessive daily somnolence (EDS) despite the treatment Epworth Sleepiness Scale (ESS) score should be ≥ 14/24 during the baseline period. Main exclusion Criteria: Patients with an untreated sleep apnea syndrome (respiratory disorder index &gt; 30/h) or who have any other cause of daytime sleepiness as assessed on patient history. Psychiatric and neurological disorders, other than narcolepsy/cataplexy, such as Parkinson's disease, Alzheimer's disease, Huntington's Chorea, multiple sclerosis, moderate or severe psychosis or dementia, bipolar illness, epilepsy, severe clinical anxiety or depression, Beck Depression Inventory ≥ 21 or with suicidal risk (if item &gt; 0), or other problem that in the investigator's opinion would preclude the patient's participation and completion of this trial or comprise reliable representation of subjective symptoms. Contraindication to flecainide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>